Logo
x

Search

Subscribe Now

intellia therapeutics

Intellia Therapeutics Reports the First Patient Dosing in P-III (MAGNITUDE-2) Trial of Nexiguran Ziclumeran for ATTRv-PN

Intellia Therapeutics Reports the First Patient Dosing in P-III (MAGNITUDE-2) Trial of Nexiguran Ziclumeran for ATTRv-PN

  • April 7, 2025
Intellia Therapeutics’ Nexiguran Ziclumeran Secures the US FDA’s RMAT Designation to Treat Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics’ Nexiguran Ziclumeran Secures the US FDA’s RMAT Designation to Treat Hereditary Transthyretin (ATTR) Amyloid...

  • November 26, 2024
Intellia Therapeutics and ReCode Therapeutics Enter into a Collaboration Agreement to Develop Novel Gene Editing Therapies for Cystic Fibrosis (CF)

Intellia Therapeutics and ReCode Therapeutics Enter into a Collaboration Agreement to Develop Novel Gene Editing Therapies for Cys...

  • February 17, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.